カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

腹圧性尿失禁治療薬のグローバル市場2023：α-アドレナリン作動薬、抗コリン薬、デュロキセチン

■ 英語タイトル：Global Medicine for Stress Incontinence Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23AG11456）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23AG11456
■ 発行日：2023年8月
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：116
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[腹圧性尿失禁治療薬のグローバル市場2023：α-アドレナリン作動薬、抗コリン薬、デュロキセチン]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Global Info Research社の最新の調査によると、腹圧性尿失禁治療薬のグローバル市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
本調査レポートは、世界の腹圧性尿失禁治療薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本資料の主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 腹圧性尿失禁治療薬の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

腹圧性尿失禁治療薬市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメント
・α-アドレナリン作動薬、抗コリン薬、デュロキセチン

用途別セグメント
・病院、クリニック、その他

主要な市場プレーヤー
・Pfizer、Johnson & Johnson、Astellas Pharma、Novartis、Teva Pharmaceutical Industries、Mylan、Sanofi、GlaxoSmithKline、Merck、Eli Lilly and Company、AstraZeneca、Bayer、Ferring Pharmaceuticals、Endo International、Allergan

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、腹圧性尿失禁治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な腹圧性尿失禁治療薬メーカーの企業概要、2019年～2022年までの腹圧性尿失禁治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な腹圧性尿失禁治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別腹圧性尿失禁治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの腹圧性尿失禁治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での腹圧性尿失禁治療薬市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および腹圧性尿失禁治療薬の産業チェーンを掲載しています。
・第14、15章では、腹圧性尿失禁治療薬の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 腹圧性尿失禁治療薬の概要
– 種類別分析（2018年vs2022年vs2029年）：α-アドレナリン作動薬、抗コリン薬、デュロキセチン
– 用途別分析（2018年vs2022年vs2029年）：病院、クリニック、その他
– 世界の腹圧性尿失禁治療薬市場規模・予測
– 世界の腹圧性尿失禁治療薬生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Pfizer、Johnson & Johnson、Astellas Pharma、Novartis、Teva Pharmaceutical Industries、Mylan、Sanofi、GlaxoSmithKline、Merck、Eli Lilly and Company、AstraZeneca、Bayer、Ferring Pharmaceuticals、Endo International、Allergan
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：α-アドレナリン作動薬、抗コリン薬、デュロキセチン
・用途別分析2018年-2029年：病院、クリニック、その他
・腹圧性尿失禁治療薬の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・腹圧性尿失禁治療薬のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・腹圧性尿失禁治療薬のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・腹圧性尿失禁治療薬の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・腹圧性尿失禁治療薬の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Medicine for Stress Incontinence
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Medicine for Stress Incontinence Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Alpha-adrenergic Agonists
1.3.3 Anticholinergics
1.3.4 Duloxetine
1.4 Market Analysis by Application
1.4.1 Overview: Global Medicine for Stress Incontinence Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Medicine for Stress Incontinence Market Size & Forecast
1.5.1 Global Medicine for Stress Incontinence Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Medicine for Stress Incontinence Sales Quantity (2018-2029)
1.5.3 Global Medicine for Stress Incontinence Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Medicine for Stress Incontinence Product and Services
2.1.4 Pfizer Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments/Updates
2.2 Johnson & Johnson
2.2.1 Johnson & Johnson Details
2.2.2 Johnson & Johnson Major Business
2.2.3 Johnson & Johnson Medicine for Stress Incontinence Product and Services
2.2.4 Johnson & Johnson Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Johnson & Johnson Recent Developments/Updates
2.3 Astellas Pharma
2.3.1 Astellas Pharma Details
2.3.2 Astellas Pharma Major Business
2.3.3 Astellas Pharma Medicine for Stress Incontinence Product and Services
2.3.4 Astellas Pharma Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Astellas Pharma Recent Developments/Updates
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Medicine for Stress Incontinence Product and Services
2.4.4 Novartis Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis Recent Developments/Updates
2.5 Teva Pharmaceutical Industries
2.5.1 Teva Pharmaceutical Industries Details
2.5.2 Teva Pharmaceutical Industries Major Business
2.5.3 Teva Pharmaceutical Industries Medicine for Stress Incontinence Product and Services
2.5.4 Teva Pharmaceutical Industries Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Teva Pharmaceutical Industries Recent Developments/Updates
2.6 Mylan
2.6.1 Mylan Details
2.6.2 Mylan Major Business
2.6.3 Mylan Medicine for Stress Incontinence Product and Services
2.6.4 Mylan Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Mylan Recent Developments/Updates
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Medicine for Stress Incontinence Product and Services
2.7.4 Sanofi Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Sanofi Recent Developments/Updates
2.8 GlaxoSmithKline
2.8.1 GlaxoSmithKline Details
2.8.2 GlaxoSmithKline Major Business
2.8.3 GlaxoSmithKline Medicine for Stress Incontinence Product and Services
2.8.4 GlaxoSmithKline Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 GlaxoSmithKline Recent Developments/Updates
2.9 Merck
2.9.1 Merck Details
2.9.2 Merck Major Business
2.9.3 Merck Medicine for Stress Incontinence Product and Services
2.9.4 Merck Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Merck Recent Developments/Updates
2.10 Eli Lilly and Company
2.10.1 Eli Lilly and Company Details
2.10.2 Eli Lilly and Company Major Business
2.10.3 Eli Lilly and Company Medicine for Stress Incontinence Product and Services
2.10.4 Eli Lilly and Company Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Eli Lilly and Company Recent Developments/Updates
2.11 AstraZeneca
2.11.1 AstraZeneca Details
2.11.2 AstraZeneca Major Business
2.11.3 AstraZeneca Medicine for Stress Incontinence Product and Services
2.11.4 AstraZeneca Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 AstraZeneca Recent Developments/Updates
2.12 Bayer
2.12.1 Bayer Details
2.12.2 Bayer Major Business
2.12.3 Bayer Medicine for Stress Incontinence Product and Services
2.12.4 Bayer Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Bayer Recent Developments/Updates
2.13 Ferring Pharmaceuticals
2.13.1 Ferring Pharmaceuticals Details
2.13.2 Ferring Pharmaceuticals Major Business
2.13.3 Ferring Pharmaceuticals Medicine for Stress Incontinence Product and Services
2.13.4 Ferring Pharmaceuticals Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Ferring Pharmaceuticals Recent Developments/Updates
2.14 Endo International
2.14.1 Endo International Details
2.14.2 Endo International Major Business
2.14.3 Endo International Medicine for Stress Incontinence Product and Services
2.14.4 Endo International Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Endo International Recent Developments/Updates
2.15 Allergan
2.15.1 Allergan Details
2.15.2 Allergan Major Business
2.15.3 Allergan Medicine for Stress Incontinence Product and Services
2.15.4 Allergan Medicine for Stress Incontinence Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Allergan Recent Developments/Updates
3 Competitive Environment: Medicine for Stress Incontinence by Manufacturer
3.1 Global Medicine for Stress Incontinence Sales Quantity by Manufacturer (2018-2023)
3.2 Global Medicine for Stress Incontinence Revenue by Manufacturer (2018-2023)
3.3 Global Medicine for Stress Incontinence Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Medicine for Stress Incontinence by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Medicine for Stress Incontinence Manufacturer Market Share in 2022
3.4.2 Top 6 Medicine for Stress Incontinence Manufacturer Market Share in 2022
3.5 Medicine for Stress Incontinence Market: Overall Company Footprint Analysis
3.5.1 Medicine for Stress Incontinence Market: Region Footprint
3.5.2 Medicine for Stress Incontinence Market: Company Product Type Footprint
3.5.3 Medicine for Stress Incontinence Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Medicine for Stress Incontinence Market Size by Region
4.1.1 Global Medicine for Stress Incontinence Sales Quantity by Region (2018-2029)
4.1.2 Global Medicine for Stress Incontinence Consumption Value by Region (2018-2029)
4.1.3 Global Medicine for Stress Incontinence Average Price by Region (2018-2029)
4.2 North America Medicine for Stress Incontinence Consumption Value (2018-2029)
4.3 Europe Medicine for Stress Incontinence Consumption Value (2018-2029)
4.4 Asia-Pacific Medicine for Stress Incontinence Consumption Value (2018-2029)
4.5 South America Medicine for Stress Incontinence Consumption Value (2018-2029)
4.6 Middle East and Africa Medicine for Stress Incontinence Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Medicine for Stress Incontinence Sales Quantity by Type (2018-2029)
5.2 Global Medicine for Stress Incontinence Consumption Value by Type (2018-2029)
5.3 Global Medicine for Stress Incontinence Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Medicine for Stress Incontinence Sales Quantity by Application (2018-2029)
6.2 Global Medicine for Stress Incontinence Consumption Value by Application (2018-2029)
6.3 Global Medicine for Stress Incontinence Average Price by Application (2018-2029)
7 North America
7.1 North America Medicine for Stress Incontinence Sales Quantity by Type (2018-2029)
7.2 North America Medicine for Stress Incontinence Sales Quantity by Application (2018-2029)
7.3 North America Medicine for Stress Incontinence Market Size by Country
7.3.1 North America Medicine for Stress Incontinence Sales Quantity by Country (2018-2029)
7.3.2 North America Medicine for Stress Incontinence Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Medicine for Stress Incontinence Sales Quantity by Type (2018-2029)
8.2 Europe Medicine for Stress Incontinence Sales Quantity by Application (2018-2029)
8.3 Europe Medicine for Stress Incontinence Market Size by Country
8.3.1 Europe Medicine for Stress Incontinence Sales Quantity by Country (2018-2029)
8.3.2 Europe Medicine for Stress Incontinence Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Medicine for Stress Incontinence Market Size by Region
9.3.1 Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Medicine for Stress Incontinence Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Medicine for Stress Incontinence Sales Quantity by Type (2018-2029)
10.2 South America Medicine for Stress Incontinence Sales Quantity by Application (2018-2029)
10.3 South America Medicine for Stress Incontinence Market Size by Country
10.3.1 South America Medicine for Stress Incontinence Sales Quantity by Country (2018-2029)
10.3.2 South America Medicine for Stress Incontinence Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Medicine for Stress Incontinence Market Size by Country
11.3.1 Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Medicine for Stress Incontinence Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Medicine for Stress Incontinence Market Drivers
12.2 Medicine for Stress Incontinence Market Restraints
12.3 Medicine for Stress Incontinence Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Medicine for Stress Incontinence and Key Manufacturers
13.2 Manufacturing Costs Percentage of Medicine for Stress Incontinence
13.3 Medicine for Stress Incontinence Production Process
13.4 Medicine for Stress Incontinence Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Medicine for Stress Incontinence Typical Distributors
14.3 Medicine for Stress Incontinence Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Medicine for Stress Incontinence Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Medicine for Stress Incontinence Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Medicine for Stress Incontinence Product and Services
Table 6. Pfizer Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Pfizer Recent Developments/Updates
Table 8. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 9. Johnson & Johnson Major Business
Table 10. Johnson & Johnson Medicine for Stress Incontinence Product and Services
Table 11. Johnson & Johnson Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Johnson & Johnson Recent Developments/Updates
Table 13. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 14. Astellas Pharma Major Business
Table 15. Astellas Pharma Medicine for Stress Incontinence Product and Services
Table 16. Astellas Pharma Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Astellas Pharma Recent Developments/Updates
Table 18. Novartis Basic Information, Manufacturing Base and Competitors
Table 19. Novartis Major Business
Table 20. Novartis Medicine for Stress Incontinence Product and Services
Table 21. Novartis Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Novartis Recent Developments/Updates
Table 23. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 24. Teva Pharmaceutical Industries Major Business
Table 25. Teva Pharmaceutical Industries Medicine for Stress Incontinence Product and Services
Table 26. Teva Pharmaceutical Industries Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Teva Pharmaceutical Industries Recent Developments/Updates
Table 28. Mylan Basic Information, Manufacturing Base and Competitors
Table 29. Mylan Major Business
Table 30. Mylan Medicine for Stress Incontinence Product and Services
Table 31. Mylan Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Mylan Recent Developments/Updates
Table 33. Sanofi Basic Information, Manufacturing Base and Competitors
Table 34. Sanofi Major Business
Table 35. Sanofi Medicine for Stress Incontinence Product and Services
Table 36. Sanofi Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Sanofi Recent Developments/Updates
Table 38. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 39. GlaxoSmithKline Major Business
Table 40. GlaxoSmithKline Medicine for Stress Incontinence Product and Services
Table 41. GlaxoSmithKline Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. GlaxoSmithKline Recent Developments/Updates
Table 43. Merck Basic Information, Manufacturing Base and Competitors
Table 44. Merck Major Business
Table 45. Merck Medicine for Stress Incontinence Product and Services
Table 46. Merck Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Merck Recent Developments/Updates
Table 48. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 49. Eli Lilly and Company Major Business
Table 50. Eli Lilly and Company Medicine for Stress Incontinence Product and Services
Table 51. Eli Lilly and Company Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Eli Lilly and Company Recent Developments/Updates
Table 53. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 54. AstraZeneca Major Business
Table 55. AstraZeneca Medicine for Stress Incontinence Product and Services
Table 56. AstraZeneca Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. AstraZeneca Recent Developments/Updates
Table 58. Bayer Basic Information, Manufacturing Base and Competitors
Table 59. Bayer Major Business
Table 60. Bayer Medicine for Stress Incontinence Product and Services
Table 61. Bayer Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Bayer Recent Developments/Updates
Table 63. Ferring Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 64. Ferring Pharmaceuticals Major Business
Table 65. Ferring Pharmaceuticals Medicine for Stress Incontinence Product and Services
Table 66. Ferring Pharmaceuticals Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Ferring Pharmaceuticals Recent Developments/Updates
Table 68. Endo International Basic Information, Manufacturing Base and Competitors
Table 69. Endo International Major Business
Table 70. Endo International Medicine for Stress Incontinence Product and Services
Table 71. Endo International Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Endo International Recent Developments/Updates
Table 73. Allergan Basic Information, Manufacturing Base and Competitors
Table 74. Allergan Major Business
Table 75. Allergan Medicine for Stress Incontinence Product and Services
Table 76. Allergan Medicine for Stress Incontinence Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Allergan Recent Developments/Updates
Table 78. Global Medicine for Stress Incontinence Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 79. Global Medicine for Stress Incontinence Revenue by Manufacturer (2018-2023) & (USD Million)
Table 80. Global Medicine for Stress Incontinence Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 81. Market Position of Manufacturers in Medicine for Stress Incontinence, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 82. Head Office and Medicine for Stress Incontinence Production Site of Key Manufacturer
Table 83. Medicine for Stress Incontinence Market: Company Product Type Footprint
Table 84. Medicine for Stress Incontinence Market: Company Product Application Footprint
Table 85. Medicine for Stress Incontinence New Market Entrants and Barriers to Market Entry
Table 86. Medicine for Stress Incontinence Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Medicine for Stress Incontinence Sales Quantity by Region (2018-2023) & (K Units)
Table 88. Global Medicine for Stress Incontinence Sales Quantity by Region (2024-2029) & (K Units)
Table 89. Global Medicine for Stress Incontinence Consumption Value by Region (2018-2023) & (USD Million)
Table 90. Global Medicine for Stress Incontinence Consumption Value by Region (2024-2029) & (USD Million)
Table 91. Global Medicine for Stress Incontinence Average Price by Region (2018-2023) & (US$/Unit)
Table 92. Global Medicine for Stress Incontinence Average Price by Region (2024-2029) & (US$/Unit)
Table 93. Global Medicine for Stress Incontinence Sales Quantity by Type (2018-2023) & (K Units)
Table 94. Global Medicine for Stress Incontinence Sales Quantity by Type (2024-2029) & (K Units)
Table 95. Global Medicine for Stress Incontinence Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Global Medicine for Stress Incontinence Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Global Medicine for Stress Incontinence Average Price by Type (2018-2023) & (US$/Unit)
Table 98. Global Medicine for Stress Incontinence Average Price by Type (2024-2029) & (US$/Unit)
Table 99. Global Medicine for Stress Incontinence Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Global Medicine for Stress Incontinence Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Global Medicine for Stress Incontinence Consumption Value by Application (2018-2023) & (USD Million)
Table 102. Global Medicine for Stress Incontinence Consumption Value by Application (2024-2029) & (USD Million)
Table 103. Global Medicine for Stress Incontinence Average Price by Application (2018-2023) & (US$/Unit)
Table 104. Global Medicine for Stress Incontinence Average Price by Application (2024-2029) & (US$/Unit)
Table 105. North America Medicine for Stress Incontinence Sales Quantity by Type (2018-2023) & (K Units)
Table 106. North America Medicine for Stress Incontinence Sales Quantity by Type (2024-2029) & (K Units)
Table 107. North America Medicine for Stress Incontinence Sales Quantity by Application (2018-2023) & (K Units)
Table 108. North America Medicine for Stress Incontinence Sales Quantity by Application (2024-2029) & (K Units)
Table 109. North America Medicine for Stress Incontinence Sales Quantity by Country (2018-2023) & (K Units)
Table 110. North America Medicine for Stress Incontinence Sales Quantity by Country (2024-2029) & (K Units)
Table 111. North America Medicine for Stress Incontinence Consumption Value by Country (2018-2023) & (USD Million)
Table 112. North America Medicine for Stress Incontinence Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Europe Medicine for Stress Incontinence Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Europe Medicine for Stress Incontinence Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Europe Medicine for Stress Incontinence Sales Quantity by Application (2018-2023) & (K Units)
Table 116. Europe Medicine for Stress Incontinence Sales Quantity by Application (2024-2029) & (K Units)
Table 117. Europe Medicine for Stress Incontinence Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Europe Medicine for Stress Incontinence Sales Quantity by Country (2024-2029) & (K Units)
Table 119. Europe Medicine for Stress Incontinence Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Medicine for Stress Incontinence Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Type (2018-2023) & (K Units)
Table 122. Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Type (2024-2029) & (K Units)
Table 123. Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Application (2018-2023) & (K Units)
Table 124. Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Application (2024-2029) & (K Units)
Table 125. Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Region (2018-2023) & (K Units)
Table 126. Asia-Pacific Medicine for Stress Incontinence Sales Quantity by Region (2024-2029) & (K Units)
Table 127. Asia-Pacific Medicine for Stress Incontinence Consumption Value by Region (2018-2023) & (USD Million)
Table 128. Asia-Pacific Medicine for Stress Incontinence Consumption Value by Region (2024-2029) & (USD Million)
Table 129. South America Medicine for Stress Incontinence Sales Quantity by Type (2018-2023) & (K Units)
Table 130. South America Medicine for Stress Incontinence Sales Quantity by Type (2024-2029) & (K Units)
Table 131. South America Medicine for Stress Incontinence Sales Quantity by Application (2018-2023) & (K Units)
Table 132. South America Medicine for Stress Incontinence Sales Quantity by Application (2024-2029) & (K Units)
Table 133. South America Medicine for Stress Incontinence Sales Quantity by Country (2018-2023) & (K Units)
Table 134. South America Medicine for Stress Incontinence Sales Quantity by Country (2024-2029) & (K Units)
Table 135. South America Medicine for Stress Incontinence Consumption Value by Country (2018-2023) & (USD Million)
Table 136. South America Medicine for Stress Incontinence Consumption Value by Country (2024-2029) & (USD Million)
Table 137. Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Type (2018-2023) & (K Units)
Table 138. Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Type (2024-2029) & (K Units)
Table 139. Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Application (2018-2023) & (K Units)
Table 140. Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Application (2024-2029) & (K Units)
Table 141. Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Region (2018-2023) & (K Units)
Table 142. Middle East & Africa Medicine for Stress Incontinence Sales Quantity by Region (2024-2029) & (K Units)
Table 143. Middle East & Africa Medicine for Stress Incontinence Consumption Value by Region (2018-2023) & (USD Million)
Table 144. Middle East & Africa Medicine for Stress Incontinence Consumption Value by Region (2024-2029) & (USD Million)
Table 145. Medicine for Stress Incontinence Raw Material
Table 146. Key Manufacturers of Medicine for Stress Incontinence Raw Materials
Table 147. Medicine for Stress Incontinence Typical Distributors
Table 148. Medicine for Stress Incontinence Typical Customers
List of Figures
Figure 1. Medicine for Stress Incontinence Picture
Figure 2. Global Medicine for Stress Incontinence Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Medicine for Stress Incontinence Consumption Value Market Share by Type in 2022
Figure 4. Alpha-adrenergic Agonists Examples
Figure 5. Anticholinergics Examples
Figure 6. Duloxetine Examples
Figure 7. Global Medicine for Stress Incontinence Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Medicine for Stress Incontinence Consumption Value Market Share by Application in 2022
Figure 9. Hospital Examples
Figure 10. Clinic Examples
Figure 11. Others Examples
Figure 12. Global Medicine for Stress Incontinence Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Medicine for Stress Incontinence Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Medicine for Stress Incontinence Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Medicine for Stress Incontinence Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Medicine for Stress Incontinence Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Medicine for Stress Incontinence Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Medicine for Stress Incontinence by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Medicine for Stress Incontinence Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Medicine for Stress Incontinence Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Medicine for Stress Incontinence Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Medicine for Stress Incontinence Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Medicine for Stress Incontinence Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Medicine for Stress Incontinence Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Medicine for Stress Incontinence Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Medicine for Stress Incontinence Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Medicine for Stress Incontinence Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Medicine for Stress Incontinence Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Medicine for Stress Incontinence Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Medicine for Stress Incontinence Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Medicine for Stress Incontinence Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Medicine for Stress Incontinence Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Medicine for Stress Incontinence Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Medicine for Stress Incontinence Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Medicine for Stress Incontinence Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Medicine for Stress Incontinence Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Medicine for Stress Incontinence Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Medicine for Stress Incontinence Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Medicine for Stress Incontinence Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Medicine for Stress Incontinence Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Medicine for Stress Incontinence Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Medicine for Stress Incontinence Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Medicine for Stress Incontinence Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Medicine for Stress Incontinence Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Medicine for Stress Incontinence Consumption Value Market Share by Region (2018-2029)
Figure 54. China Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Medicine for Stress Incontinence Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Medicine for Stress Incontinence Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Medicine for Stress Incontinence Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Medicine for Stress Incontinence Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Medicine for Stress Incontinence Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Medicine for Stress Incontinence Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Medicine for Stress Incontinence Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Medicine for Stress Incontinence Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Medicine for Stress Incontinence Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Medicine for Stress Incontinence Market Drivers
Figure 75. Medicine for Stress Incontinence Market Restraints
Figure 76. Medicine for Stress Incontinence Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Medicine for Stress Incontinence in 2022
Figure 79. Manufacturing Process Analysis of Medicine for Stress Incontinence
Figure 80. Medicine for Stress Incontinence Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 切迫性尿失禁治療薬のグローバル市場2023：抗コリン薬、β3刺激薬、その他
  • セロトニン&ノルアドレナリン再取り込み阻害剤のグローバル市場2023：ベンラファクシン、デュロキセチン、デスベンラファクシン、レボミルナシプラン
  • 眼瞼痙攣治療薬のグローバル市場展望 2023年-2029年：抗コリン薬、ベンゾジアゼピン薬、ドーパミン薬、抗けいれん薬、その他
  • 神経疾患治療薬のグローバル市場展望 2023年-2029年：抗コリン薬、抗てんかん薬、抗精神病薬、催眠鎮静薬、鎮痛薬、降圧薬、抗凝固薬、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23AG11456 )"腹圧性尿失禁治療薬のグローバル市場2023：α-アドレナリン作動薬、抗コリン薬、デュロキセチン" (英文：Global Medicine for Stress Incontinence Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。